Compare Stocks → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AGLENASDAQ:LUMONYSE:NHWKNASDAQ:ONTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGLEAeglea BioTherapeutics$11.47$2.66▼$32.75$48.64M2.5795,409 shs43,300 shsLUMOLumos Pharma$2.83+2.5%$2.83$2.41▼$4.55$22.94M0.6520,312 shs688 shsNHWKNightHawk Biosciences$0.39$0.26▼$1.16$10.78M0.1997,242 shs173,100 shsONTXOnconova Therapeutics$0.84$0.55▼$1.45$20.90M1.3896,681 shs1.28 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGLEAeglea BioTherapeutics0.00%0.00%0.00%0.00%+199.13%LUMOLumos Pharma-2.13%+5.34%-3.50%-4.00%-12.10%NHWKNightHawk Biosciences0.00%0.00%0.00%+12.09%-39.19%ONTXOnconova Therapeutics0.00%0.00%+10.59%+40.84%-5.21%Move Your Money Before May 1 (Ad)Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALUMOLumos Pharma1.5791 of 5 stars3.51.00.00.00.02.51.3NHWKNightHawk BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AONTXOnconova Therapeutics0.7655 of 5 stars3.53.00.00.00.00.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGLEAeglea BioTherapeutics2.50Moderate Buy$17.50∞ UpsideLUMOLumos Pharma3.00Buy$18.00537.17% UpsideNHWKNightHawk BiosciencesN/AN/AN/AN/AONTXOnconova Therapeutics3.00Buy$11.00∞ UpsideCurrent Analyst RatingsLatest ONTX, NHWK, AGLE, and LUMO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2024LUMOLumos PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGLEAeglea BioTherapeutics$2.33M0.00N/AN/A($60.61) per share0.00LUMOLumos Pharma$2.05M11.19N/AN/A$3.45 per share0.82NHWKNightHawk Biosciences$6.38M0.00N/AN/A$2.82 per share0.00ONTXOnconova Therapeutics$230K0.00N/AN/A$1.35 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGLEAeglea BioTherapeutics-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/ALUMOLumos Pharma-$34.03M-$4.19N/AN/AN/A-1,659.39%-85.63%-65.30%5/1/2024 (Estimated)NHWKNightHawk Biosciences-$43.44M-$1.99N/AN/AN/A-2,333.27%-91.62%-56.48%N/AONTXOnconova Therapeutics-$18.96M-$0.91N/AN/AN/A-8,930.97%-95.43%-61.19%5/20/2024 (Estimated)Latest ONTX, NHWK, AGLE, and LUMO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023LUMOLumos Pharma-$1.18-$1.17+$0.01-$1.17$0.01 million$0.83 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/ALUMOLumos PharmaN/AN/AN/AN/AN/ANHWKNightHawk BiosciencesN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGLEAeglea BioTherapeuticsN/A4.594.59LUMOLumos PharmaN/A5.695.69NHWKNightHawk Biosciences0.270.990.99ONTXOnconova TherapeuticsN/A2.792.79OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGLEAeglea BioTherapeuticsN/ALUMOLumos Pharma33.99%NHWKNightHawk Biosciences21.16%ONTXOnconova Therapeutics7.95%Insider OwnershipCompanyInsider OwnershipAGLEAeglea BioTherapeutics6.60%LUMOLumos Pharma25.40%NHWKNightHawk Biosciences15.90%ONTXOnconova Therapeutics3.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGLEAeglea BioTherapeutics694.05 million3.78 millionOptionableLUMOLumos Pharma338.12 million6.06 millionNot OptionableNHWKNightHawk Biosciences7726.08 million21.94 millionOptionableONTXOnconova Therapeutics1621.00 million20.31 millionOptionableONTX, NHWK, AGLE, and LUMO HeadlinesSourceHeadlineOnconova Therapeutics (NASDAQ:ONTX) Now Covered by StockNews.comamericanbankingnews.com - April 24 at 2:22 AMOnconova Therapeutics (NASDAQ:ONTX) Coverage Initiated at StockNews.comamericanbankingnews.com - April 16 at 2:22 AMOnconova and Trawsfynydd merge to form Traws Pharmauk.investing.com - April 4 at 6:50 PMTraws Pharma Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - April 4 at 6:50 PMNewtown’s Onconova Therapeutics Secures $14 Million and New CEO in Merger with Trawsfynyddmsn.com - April 3 at 5:47 PMOnconova Acquires Trawsfynydd To Form Traws Pharmamarkets.businessinsider.com - April 2 at 10:00 AMTraws Pharma Announces New Employee Inducement Grantsglobenewswire.com - April 2 at 7:15 AMOnconova to Unveil New Rigosertib Study Results at Cancer Research Meetingmsn.com - March 12 at 8:48 AMAnalysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Biogen (BIIB)markets.businessinsider.com - March 11 at 1:17 PMOnconova Therapeutics’ Rigosertib Poster Selected for AACR 2024finance.yahoo.com - March 8 at 9:56 AMOnconova Therapeutics' Rigosertib Poster Selected for AACR 2024globenewswire.com - March 8 at 8:00 AMOnconova Therapeutics Inc (ONTX)investing.com - February 13 at 12:22 AMOnconova Therapeutics, Inc. (ONTX)finance.yahoo.com - January 23 at 10:41 PMOnconova Therapeutics Stock (NASDAQ:ONTX) Dividends: History, Yield and Datesbenzinga.com - December 21 at 11:07 PMOnconova stock falls 10% on preclinical data for lymphoma drugmsn.com - December 12 at 4:02 PMOnconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphomafinance.yahoo.com - December 12 at 9:55 AMOnconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’sfinance.yahoo.com - December 8 at 6:47 PMOnconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conferencefinance.yahoo.com - November 28 at 10:06 AMOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 16 at 12:48 PMOnconova Therapeutics, Inc.: Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Resultsfinanznachrichten.de - November 16 at 1:30 AMOnconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 14 at 6:28 PMOnconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023finance.yahoo.com - November 7 at 5:22 PMOnconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCLbenzinga.com - November 2 at 7:56 PMOnconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCLfinance.yahoo.com - November 2 at 2:55 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 months3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture Comeback3 Value Stocks Buffett Wishes He Could BuyApril 22, 2024 8:35 AMView 3 Value Stocks Buffett Wishes He Could BuyGold Rush: Exploring 5 Sector Giants Amidst Soaring PricesApril 4, 2024 6:10 AMView Gold Rush: Exploring 5 Sector Giants Amidst Soaring PricesAll Headlines Company DescriptionsAeglea BioTherapeuticsNASDAQ:AGLEAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.Lumos PharmaNASDAQ:LUMOLumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.NightHawk BiosciencesNYSE:NHWKNightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.Onconova TherapeuticsNASDAQ:ONTXOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.